Head-to-head · Cost-Efficiency Index
Invigor Medical vs Maves
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalMaves
Cost-first shoppers who want $99 first-month semaglutide with men's-health and body-optimization framing.
Visit MavesThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 76. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. Maves still earns a C — Cost-first shoppers who want $99 first-month semaglutide with men's-health and body-optimization framing.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | Maves |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 76/100 |
| Semaglutide / mo | $199/mo | $99/mo (starting dose, first-month rate, compounded) |
| Tirzepatide / mo | $339/mo | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | $1,188 |
| Tirzepatide / yr (modeled) | $4,068 | — |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #8 | #49 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
Maves
76/100Where the value is
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
The tradeoffs
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.